CJC-1295 + Ipamorelin vs CJC-1295 (with DAC)

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is a dual-peptide formulation combining a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. These two peptides operate through complementary mechanisms: CJC-1295 (without DAC) stimulates GH release by binding GHRH receptors on pituitary somatotrophs and amplifying the baseline GH pulse, while ipamorelin activates the ghrelin receptor to initiate a separate GH release signal. When used together, research indicates a synergistic amplification of GH pulsatility that exceeds the additive effects of either peptide alone. This synergy was characterized in studies examining GHRH-GHRP combined use, where combined studies produced GH peaks 2-3 times greater than single-agent studies (Bowers et al., Endocrinology). Ipamorelin is distinguished among ghrelin mimetics by its high selectivity for GH release without significantly elevating cortisol, prolactin, or ACTH levels, as demonstrated in clinical studies (Raun et al., European Journal of Endocrinology, 1998). CJC-1295 without DAC has a half-life of approximately 30 minutes, producing acute GH pulses rather than sustained elevation. Compared to GHRP-6, which broadly activates ghrelin receptors causing appetite stimulation, ipamorelin offers cleaner GH release profiles. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This combination is widely studied by endocrinology research labs, sports medicine institutions, and body composition research centers investigating modulated GH secretagogue studies.

CJC-1295 (with DAC)

CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue conjugated with a maleimidopropionic acid (MPA) linker that binds covalently to serum albumin after entering circulation. This albumin conjugation dramatically extends the peptide's half-life from approximately 30 minutes to 6-8 days, enabling sustained elevation of growth hormone levels from a single use. The mechanism involves the same GHRH receptor activation as the non-DAC version, but the prolonged pharmacokinetic profile produces continuous rather than pulsatile GH stimulation. In a pivotal pharmacokinetic study, Teichman et al. Compared to CJC-1295 without DAC, the DAC version is suited for research studies requiring prolonged GH axis stimulation, while the non-DAC form better models physiological pulse dynamics. Research also suggests potential applications in lean mass preservation, bone mineral density, and sleep quality improvement through sustained GH pathway activation. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This compound is studied by endocrinology research programs, pharmacokinetics laboratories, and institutions investigating sustained-release peptide delivery strategies.

Frequently Asked Questions